Bioxiness Pharmaceuticals, Inc. is a privately-owned company headquartered in Hercules, California. It was founded in 2007 to address the emerging global threat of infectious diseases by discovering and developing a new class of small molecule antibiotic medicines.
First-generation Bioxiness compounds have a promising pharmacological profile: they have minimal toxicity, act on a bacterial target against which no drug resistance has yet developed, and have anti-microbial activity against several Gram-negative and Gram-positive pathogens.
In its Threat Report 2013, the US Centers for Disease Control estimates that 2 million infections will be drug resistant to some antibiotics. An estimated 23,000 Americans will die from infections. The additional costs of treating drug-resistant infections is estimated to be $20BN in direct healthcare spending and $35BN in lost economic productivity.1
In 2012, Dr. Margaret Chan, Director-General of the World Health Organization warned that “A post-antibiotic era means, in effect, an end to modern medicine as we know it. Things as common as strep throat or a child’s scratched knee could once again kill.”2